Rankings
▼
Calendar
CTMX Q2 2018 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$822M
Q2 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$21M
+143.8% YoY
Gross Profit
$21M
100.0% margin
Operating Income
-$13M
-62.1% margin
Net Income
-$13M
-63.0% margin
EPS (Diluted)
$-0.35
QoQ Revenue Growth
+50.4%
Cash Flow
Operating Cash Flow
-$27M
Free Cash Flow
-$27M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$377M
Total Liabilities
$336M
Stockholders' Equity
$41M
Cash & Equivalents
$133M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$21M
$9M
+143.8%
Gross Profit
$21M
$9M
+143.8%
Operating Income
-$13M
-$25M
+47.8%
Net Income
-$13M
-$25M
+46.7%
Revenue Segments
E G F R Products
$42M
91%
Amgen Other Products
$4M
9%
← FY 2018
All Quarters
Q3 2018 →